Early research (Phase 1)Active Not RecruitingNCT03101891What this trial is testingRenal Anhydramnios Fetal TherapyWho this might be right forAnhydramniosPotter SyndromeLung Hypoplasia+4 more Johns Hopkins University 70
Not applicableLooking for participantsNCT06728228What this trial is testingAmnioinfusion for Fetal Renal FailureWho this might be right forMulticystic Dysplastic KidneyPolycystic Kidney DiseaseFetal Renal Anomaly+6 more Fetal Care Center, PLLC 35
Large-scale testing (Phase 3)Looking for participantsNCT04782258What this trial is testingSee Iftolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old withAutosomal Recessive Polycystic Kidney Disease (ARPKD)Who this might be right forAutosomal Recessive Polycystic Kidney (ARPKD) Otsuka Pharmaceutical Development & Commercialization, Inc. 20
Large-scale testing (Phase 3)WithdrawnNCT04786574What this trial is testingSee if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)Who this might be right forAutosomal Recessive Polycystic Kidney Disease (ARPKD) Otsuka Pharmaceutical Development & Commercialization, Inc.